Hot Features
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that i... Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -3.4188034188 | 1.17 | 1.18 | 1.11 | 383434 | 1.14133827 | CS |
| 4 | -0.12 | -9.6 | 1.25 | 1.275 | 1.11 | 476923 | 1.16757624 | CS |
| 12 | -0.21 | -15.671641791 | 1.34 | 1.38 | 1.11 | 476264 | 1.2198729 | CS |
| 26 | -0.1 | -8.13008130081 | 1.23 | 1.42 | 1.09 | 633586 | 1.2454308 | CS |
| 52 | -0.25 | -18.115942029 | 1.38 | 1.95 | 1.09 | 891043 | 1.39121128 | CS |
| 156 | -19.41 | -94.4985394352 | 20.54 | 20.66 | 1.09 | 840854 | 5.99708367 | CS |
| 260 | -28.39 | -96.1720867209 | 29.52 | 36.64 | 1.09 | 744972 | 11.13394597 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.